Bronchoalveolar Cell Lung Cancer Completed Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0028477 (Bronchoalveolar Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00040794Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment
NCT00368992S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerTreatment